Evidence map›Paper›PMID 42230495›Full record

ArticleBulletin of experimental biology and medicine2026

Effect of Antitubercular Drug Macozinone (PBTZ169) on the Intestinal Microbiota and Immunity in Inbred Mice.

B V Nikonenko, I V Bocharova, A E Donnikov, S I Kajukova, D V Dianov, V A Makarov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

B V NikonenkoCentral Tuberculosis Research Institute, Moscow, Russia. boris.nikonenko52@gmail.com.
I V BocharovaCentral Tuberculosis Research Institute, Moscow, Russia.
A E DonnikovCentral Tuberculosis Research Institute, Moscow, Russia.
S I KajukovaCentral Tuberculosis Research Institute, Moscow, Russia.
D V DianovCentral Tuberculosis Research Institute, Moscow, Russia.
V A MakarovCentral Tuberculosis Research Institute, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inbred BALB/c mice were intragastrically administered with a new antitubercular compound macozinone (PBTZ169) or a combination of isoniazid, rifampicin, and pyrazinamide (HRZ) for six months; control animals received no antitubercular drugs. After 6 months, the microbiota of the large intestine was analyzed. Unlike HRZ combination, macozinone practically does not affect the microbiota: its composition remained the same as in the control group. In lung tissue, differences in the expression of some genes regulating the immune response were found. Two months post-infection with Mycobacterium tuberculosis, mice treated with either the HRZ combination or macozinone exhibited distinct immune responses to tuberculin.

Indexed as

Antitubercular AgentsGastrointestinal MicrobiomeTuberculosisAnimalsFemaleIsoniazidLungMaleMiceMice, Inbred BALB CMycobacterium tuberculosisPyrazinamideRifampinAntitubercular AgentsIsoniazidPyrazinamideRifampinantitubercular drugsimmune responseinbred miceintestinal microbiotamacozinone

Identifiers

PMID42230495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.